EQRx (NASDAQ:EQRX) Now Covered by Analysts at Cowen

Cowen began coverage on shares of EQRx (NASDAQ:EQRXGet Rating) in a research note issued to investors on Friday, Benzinga reports. The firm set an “outperform” rating on the stock.

Separately, Jefferies Financial Group initiated coverage on shares of EQRx in a report on Friday, March 18th. They issued a “buy” rating and a $5.60 price target for the company.

EQRx stock opened at $4.42 on Friday. The firm has a 50 day simple moving average of $3.77. EQRx has a 12 month low of $2.63 and a 12 month high of $11.10.

Hedge funds have recently bought and sold shares of the stock. Exos Asset Management LLC purchased a new stake in EQRx during the 4th quarter worth approximately $59,000. Advisor Group Holdings Inc. purchased a new stake in shares of EQRx during the fourth quarter worth approximately $67,000. Penserra Capital Management LLC acquired a new position in EQRx in the 4th quarter valued at $82,000. Brown Advisory Inc. acquired a new position in EQRx in the 4th quarter valued at $84,000. Finally, Family Management Corp purchased a new position in EQRx in the 4th quarter valued at $102,000. Institutional investors own 19.99% of the company’s stock.

EQRx Company Profile (Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.

Read More

Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.